Literature DB >> 1402801

Stimulation of specific immune responses to simian immunodeficiency virus using chimeric hepatitis B core antigen particles.

J Yon1, E Rud, T Corcoran, K Kent, D Rowlands, B Clarke.   

Abstract

Subunit approaches to vaccines against viral diseases have resulted in the development of a number of methods for presentation of defined epitopes to the immune system. We have exploited a highly immunogenic presentation system based on hepatitis B core antigen (HBcAg) particles to produce a number of candidate vaccines against simian immunodeficiency virus (SIV). Recombinant particles have been produced in bacteria which carry multiple copies of defined or predicted neutralizing epitopes of SIV at a number of different sites within the particle. In parallel, a number of synthetic peptide-based SIV vaccines have been produced based on homology to reported neutralizing epitopes in human immunodeficiency virus. Although potent immune responses were elicited against both particulate and peptide forms of the antigen, neutralizing antibodies were not induced as judged by available assays.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1402801     DOI: 10.1099/0022-1317-73-10-2569

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  3 in total

1.  Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein.

Authors:  A Yoshikawa; T Tanaka; Y Hoshi; N Kato; K Tachibana; H Iizuka; A Machida; H Okamoto; M Yamasaki; Y Miyakawa
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

Review 2.  Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines.

Authors:  G P Lomonossoff; J E Johnson
Journal:  Curr Opin Struct Biol       Date:  1996-04       Impact factor: 6.809

3.  The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.

Authors:  Andris Dishlers; Dace Skrastina; Regina Renhofa; Ivars Petrovskis; Velta Ose; Ilva Lieknina; Juris Jansons; Paul Pumpens; Irina Sominskaya
Journal:  Mol Biotechnol       Date:  2015-12       Impact factor: 2.695

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.